Butambala, Mpigi, Mityana, Gomba Districts
Gombe, Uganda
NCT Number: NCT02545673
The purpose of this study is to evaluate the effectiveness of a linkage to care intervention at achieving HIV viral suppression and intermediate outcomes of linkage/time to care, time to /receipt of opportunistic infection prophylaxis, and antiretroviral therapy (ART) among people testing HIV positive during home-based HIV counseling and testing (HBHCT) in rural Uganda.
Looking for future studies?
Notify Me18 year–59 year
All sexes
Interventional
Not applicable
Gombe, Uganda
Throughout sub-Saharan Africa there is a pressing need to facilitate early and easier entry into HIV care and treatment; up to two-thirds of patients are lost to follow up between testing HIV positive and initiation of antiretroviral (ARV) treatment. Home-based HIV testing and counseling (HBHCT), which identifies those who are HIV positive at earlier disease stages than other testing approaches, is becoming a large component of many sub-Saharan African countries' HIV prevention programs, including Uganda's. Paper-based referral to care, sometimes adding follow-up home visits, is the most common linkage-to-care approach with HBHCT. Linkage to care may be challenging with HBHCT since the testing occurs in the home at a distance from a health facility. The investigators propose to test an intervention which enhances a linkage to care intervention tested in an urban Ugandan provider-initiated HIV testing setting and found to improve linkage to care. The aims of the project are: (1) In a cluster randomized trial compare the effectiveness of the enhanced linkage to care intervention vs. standard-of-care (paper based referrals) at achieving HIV viral suppression and intermediate outcomes of linkage to care, receipt of opportunistic infection prophylaxis, and ART initiation among those eligible for antiretroviral therapy (ART). (2) Using the standard-of-care group as a natural history control, collect longitudinal data on barriers to and facilitators of linkage to and retention in care and treatment and HIV viral suppression. (3) Estimate the cost-effectiveness of the intervention, as compared to standard-of-care, in terms of major study outcomes.
Participation in the full study will last 12 months. All participants will first undergo HBHCT, viral load and CD4 testing, and complete a brief questionnaire. Participants will then be randomly assigned to one of two study arms: the enhanced linkage to care intervention arm or the standard-of-care control arm. Participants in both study arms will participate in interviewer administered questionnaires at 6 months and 12 months follow-up, viral load and CD4 testing at 12 month follow-up, and will permit the research team to access their medical records to extract information about their health status and linkage to care. Participants in the intervention arm will also receive a series of counseling sessions with an HIV counselor taking place at the participant's home, clinic, and over the phone. These sessions will last approximately 30 minutes, and consist of counseling to help clients identify and reduce barriers to engagement in care, assistance disclosing and identifying a treatment supporter, and stigma reduction through increasing social support.
Healthy volunteers accepted: No
Only the study team can determine whether someone qualifies for participation.
Inclusion/Exclusion for home-based HIV counseling and testing and brief baseline questionnaire:
Inclusion criteria
Exclusion criteria
Inclusion/Exclusion for the Intervention Study:
Inclusion criteria
Exclusion criteria
Time frame: 12 months follow up
defined as HIV RNA <20 cells/ml collected via venous blood draw
Time frame: 12 months follow up
defined as HIV RNA <1000 cells/ml collected via venous blood draw
Time frame: 6 and 12 months follow up
Enrollment in an HIV clinic with a 2nd clinic visit
Time frame: 6 and 12 months follow up
Percentage of eligible participants initiating ART
Time frame: 6 and 12 months follow up
on ART at 6 and 12 month follow up: reporting taking ART at each follow-up
Time frame: 6 and 12 months follow up
Time from HIV testing to enrollment in an HIV clinic
Time frame: 6 and 12 months follow up
Time from HIV testing to receipt of ART
Time frame: 6 and 12 months follow up
Missed visit count: number of missed visits accrued (count measure) based on scheduled visits determined by Ministry of Health clinical guidelines
Time frame: 6 and 12 months follow up
Proportion of kept visits/scheduled visits (kept + missed visits)
Time frame: 6 and 12 months follow up
4-month constancy 4 month visit constancy: number of 4-month intervals with at least 1 kept visit
Time frame: 6 and 12 months follow up
The percentage of participants who received co-trimoxazole
Time frame: 6 and 12 months follow up
Time to receipt of co-trimoxazole
Susan M Kiene
Other
OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.
View the official ClinicalTrials.gov record (opens in a new tab)This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.
Published trials that share one or more normalized conditions with this study.
NCT07225894
Behavior, HIV
Kisumu, Kisumu County, Kenya
View Trial DetailsNCT06316102
Behavior, HIV
Santo Domingo, Dominican Republic
View Trial DetailsNCT05080972
Acquired Immunodeficiency Syndrome, Behavior
Atlanta, Georgia, United States
View Trial DetailsNCT05383755
Behavior, HIV
Kisumu, Kenya
View Trial Details